Safety of braf+mek inhibitor combinations: Severe adverse event evaluation

Keyphrases

• Age-adjusted 10%
• B-Raf 100%
• Binimetinib 20%
• BRAF Inhibitor (BRAFi) 90%
• BRAF V600E mutation 10%
• Class Effect 10%
• Cobimetinib 20%
• Combination Therapy 10%
• Dabrafenib 20%
• Encorafenib 20%
• Event Evaluation 100%
• Fatal Outcome 10%
• FDA Adverse Event Reporting System (FAERS) 10%
• Fever 10%
• Inhibitor Combination 100%
• MEK Inhibitor (MEKi) 100%
• Melanoma Patients 10%
• Patient Care 10%
• Patient Health 10%
• Peripheral Neuropathy 10%
• Pharmacovigilance 20%
• Renal Disease 10%
• Reporting Odds Ratio 40%
• Safety Profile 10%
• Safety Signal 10%
• Serious Adverse Events 20%
• Severe Adverse Events 100%
• Severe Outcomes 10%
• Skin Toxicity 10%
• Specific Safety 10%
• System Data 10%
• Trametinib 20%
• Vemurafenib 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 100%
• Binimetinib 66%
• Cobimetinib 66%
• Combination Therapy 33%
• Dabrafenib 66%
• Encorafenib 66%
• Fatality 33%
• FDA Adverse Event Reporting System 33%
• Kidney Disease 33%
• Melanoma 33%
• Mitogen Activated Protein Kinase Kinase Inhibitor 33%
• Neuropathy 33%
• Pharmacovigilance 66%
• Skin Toxicity 33%
• Syndrome 66%
• Trametinib 66%
• Vemurafenib 66%